7.3 Cystic Fibrosis 2016
DOI: 10.1183/13993003.congress-2016.pa4863
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and safety of inhaled antibiotics for chronicpseudomonasinfection in cystic fibrosis: Network meta-analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…To explore the potential of anCP as a carrier for diverse drug cargos, the aminoglycoside tobramycin ( M w = 467.5 Da), and the oligopeptide colistin ( M w = 1267.5 Da) were chosen as low molecular weight cargos. Tobramycin and colistin are active against Gram negative bacteria, and are two of the four drugs specifically approved in Europe for application as inhaled therapies for chronic bronchopulmonary P. aeruginosa infection in cystic fibrosis patients [ 25 , 26 , 44 ]. Fast elimination and poor permeability however often limit the delivery of hydrophilic anti-infectives, such as tobramycin and colistin, requiring frequent and high dosing with the risk of adverse drug effects and the development of bacterial resistance.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To explore the potential of anCP as a carrier for diverse drug cargos, the aminoglycoside tobramycin ( M w = 467.5 Da), and the oligopeptide colistin ( M w = 1267.5 Da) were chosen as low molecular weight cargos. Tobramycin and colistin are active against Gram negative bacteria, and are two of the four drugs specifically approved in Europe for application as inhaled therapies for chronic bronchopulmonary P. aeruginosa infection in cystic fibrosis patients [ 25 , 26 , 44 ]. Fast elimination and poor permeability however often limit the delivery of hydrophilic anti-infectives, such as tobramycin and colistin, requiring frequent and high dosing with the risk of adverse drug effects and the development of bacterial resistance.…”
Section: Resultsmentioning
confidence: 99%
“…Thus, the varied production parameters of starch-chitosan polyplexes ( Scheme 1 A) were: (i) molar ratio of carboxylate and amine functional groups (C/N ratio) of starch and chitosan, respectively; (ii) polymer concentration; and (iii) counter polymer type. The loading capacity and versatility of these simple carriers was then investigated using tobramycin and colistin as clinically relevant models of small molecule and peptide anti-infectives respectively [ 25 , 26 ], as well as nucleic acids (plasmid DNA). Furthermore, to improve encapsulation capacity, we coated the starch-chitosan polyplexes with an additional chitosan (Protasan) layer ( Scheme 1 B), and explored the loading capacity of the resulting nanoparticles.…”
Section: Introductionmentioning
confidence: 99%